Search Results

Your search for James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD,James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD matches 2 pages

Showing 1 - 2

By James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD / 2014 ASH Annual Meeting

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in...

leukemia

By James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD / 2014 ASH Annual Meeting

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Nov

Today In Oncology

Search Results

Your search for James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD,James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD matches 2 pages

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma

Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor

Healthy Women May Have Aneuploid Epithelial Cells Resembling Breast Cancer

Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma